- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00115570
Comparison of the Ability of Glulisine With Lispro to Control Type 1 Diabetes Mellitus in Children and Adolescents
May 19, 2016 updated by: Sanofi
Efficacy and Safety of Insulin Glulisine Compared With Insulin Lispro in Children and Adolescents With Type 1 Diabetes Mellitus: A 26 Week, Multicenter, Open, Parallel Clinical Trial
The purpose of this study is to determine if insulin glulisine (Apidra) is as safe and effective a rapid acting insulin as insulin lispro (Humalog) in children and adolescents with type 1 diabetes mellitus.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Actual)
572
Phase
- Phase 3
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Pennsylvania
-
Pittsburgh, Pennsylvania, United States, 15213
- Childrens Hospital of Pittsburgh
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
4 years to 17 years (CHILD)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Girls/boys, 4-17 years, inclusive;
- Girls not yet of childbearing potential or, if sexually active, agree to use reliable medically accepted contraceptive measure during study;
- Type 1 diabetes mellitus established in medical history: for example, but not limited to, clear signs of insulinopenia (polyuria, polydipsia, polyphagia, weight loss, ketonuria, ketoacidosis); or glutamic acid decarboxylase (GAD) antibody indicative of type 1 diabetes measured at any time before study; or requiring continuous insulin therapy from time of diagnosis;
- Onset of diabetes at least 1 year prior to visit 1 (V1) of study;
- Uninterrupted insulin therapy for at least 1 year before V1 of study;
- At V1, on stable insulin regimen of either NPH or insulin glargine as basal insulin and willing to have multiple daily injections of insulin;
- Glycated hemoglobin at V1 between ≥ 6.0 and ≤11.0 %;
- Ability/willingness to do blood glucose monitoring using sponsor-provided glucometer and subject diary.
Exclusion Criteria:
- Active proliferative diabetic retinopathy, defined by application of focal or panretinal photocoagulation or vitrectomy, 6 months before V1, or any other unstable/rapidly progressing retinopathy requiring surgical treatment (including laser photocoagulation) during study;
- Diabetes other than type 1 diabetes mellitus;
- Pregnancy (positive pregnancy blood test at V1) or breastfeeding;
- Pancreatectomized subjects;
- Subjects who have had pancreas and/or islet cell transplants;
- Treatment with any anti-diabetic oral agent at any time from diabetes diagnosis;
- Treatment with systemic corticosteroids in last month before V1;
- Subjects on pump therapy during last 2 months before V1;
- Subjects requiring excessively high doses of insulin ("resistant" patients), for example, but not limited to, subjects receiving over 150 IU per day;
- Likelihood of needing treatment during study period with drugs not permitted by protocol
- Treatment with any investigational drug in last month before V1;
- History of primary seizure disorders;
- History of severe hypoglycemic episode accompanied by seizure and/or coma or diabetic ketoacidosis leading to hospitalization, or to care in emergency ward, 3 months prior to V1;
- History of hypoglycemia unawareness;
- History of hypersensitivity to insulin or insulin analogs or any of the excipients in insulin glulisine formulation or any of the excipients in other study insulin preparations formulations;
- Clinically relevant hepatic, neurologic, endocrine, active cancer, or other major systemic disease making implementation of protocol or interpretation of study results difficult and would, in the opinion of the investigator, preclude safe participation of subject in protocol;
- History of cardiac abnormalities and/or cardiovascular disorders;
- History of drug/alcohol abuse;
- Impaired hepatic function shown by, but not limited to, alanine aminotransferase (ALT) or aspartate aminotransferase (AST) greater than twice the normal upper limit for age at V1;
- Impaired renal function shown by, but not limited to, serum creatinine greater than 1.5 times upper limit for age at V1;
- Non fasting triglyceride level of >500 mg/dL (5.7 mmol/L) at V1;
- Parent/legally authorized representative unable to understand nature, scope, possible consequences of study;
- Parent/legally authorized representative unable to read/write;
- Subjects unlikely to comply with protocol, e.g. inability/unwillingness to participate in adequate training, uncooperative attitude, inability to return for follow-up visits, and unlikelihood of completing study;
- Children/relatives of employee of sponsor or of sponsor representatives;
- Children or relatives of investigator, any sub-investigator, research assistant, pharmacist, study coordinator or other staff directly involved in conduct of protocol;
- Subjects who have previously been treated with insulin glulisine.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: RANDOMIZED
- Interventional Model: PARALLEL
- Masking: NONE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
EXPERIMENTAL: Insulin Glulisine
Insulin Glulisine (100UI/ml), at least twice daily, in association with basal insulin therapy (NPH insulin or insulin glargine for a maximum of 26 weeks
|
Subcutaneous injection
Other Names:
Subcutaneous injection once daily
subcutaneous injection twice daily
|
ACTIVE_COMPARATOR: Insulin Lispro
Insulin Lispro (100UI/ml) Subcutaneous (SC) injection , at least twice daily, in association with basal insulin therapy (NPH insulin or insulin glargine ) for a maximum of 30 weeks
|
Subcutaneous injection once daily
subcutaneous injection twice daily
Subcutaneous injection
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Change in total glycated hemoglobin measured as HbA1c equivalents (GHb )from baseline to endpoint
Time Frame: week 26 or last observed treatment
|
week 26 or last observed treatment
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Change from Baseline in GHb at weeks 12 and 26
Time Frame: weeks 12 and 26
|
weeks 12 and 26
|
Change from Baseline in Self-monitored glucose parameters
Time Frame: weeks 4, 12, 18, 26, and endpoint;
|
weeks 4, 12, 18, 26, and endpoint;
|
Incidence of Symptomatic hypoglycemia
Time Frame: first dose of study up to last dose
|
first dose of study up to last dose
|
Change from Baseline in basal insulin dose
Time Frame: week 4, 12, 18, 26, and endpoint;
|
week 4, 12, 18, 26, and endpoint;
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Principal Investigator: Dr Arethi PHILOTHEOU, UCT Diabetes Clinical Trials Unit - Faculty of Health Sciences - South-Africa
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
April 1, 2005
Primary Completion (ACTUAL)
November 1, 2006
Study Completion (ACTUAL)
November 1, 2006
Study Registration Dates
First Submitted
June 23, 2005
First Submitted That Met QC Criteria
June 23, 2005
First Posted (ESTIMATE)
June 24, 2005
Study Record Updates
Last Update Posted (ESTIMATE)
May 20, 2016
Last Update Submitted That Met QC Criteria
May 19, 2016
Last Verified
May 1, 2016
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Glucose Metabolism Disorders
- Metabolic Diseases
- Immune System Diseases
- Autoimmune Diseases
- Endocrine System Diseases
- Diabetes Mellitus
- Diabetes Mellitus, Type 1
- Hypoglycemic Agents
- Physiological Effects of Drugs
- Insulin
- Insulin, Globin Zinc
- Insulin Glargine
- Insulin Lispro
- Insulin glulisine
- Insulin, Isophane
- Isophane Insulin, Human
- Isophane insulin, beef
Other Study ID Numbers
- EFC6096
- HMR 1964
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Diabetes Mellitus, Insulin-Dependent
-
VeraLight, Inc.CompletedDiabetes Mellitus, Non-Insulin DependentUnited States
-
Procter and GambleTerminatedNon-Insulin-dependent Diabetes MellitusUnited States
-
Inha University HospitalCompletedNon Insulin Dependent Diabetes MellitusKorea, Republic of
-
University of Colorado, DenverMassachusetts General Hospital; Beta Bionics, Inc.CompletedDiabetes Mellitus, Type 1 | Type 1 Diabetes | Diabetes type1 | Type 1 Diabetes Mellitus | Autoimmune Diabetes | Diabetes Mellitus, Insulin-Dependent | Juvenile-Onset Diabetes | Diabetes, Autoimmune | Insulin-Dependent Diabetes Mellitus 1 | Diabetes Mellitus, Insulin-Dependent, 1 | Diabetes Mellitus, Brittle | Diabetes Mellitus, Juvenile-Onset and other conditionsUnited States
-
VeraLight, Inc.CompletedDiabetes Mellitus, Non-Insulin DependentUnited States
-
Johnson & Johnson Pharmaceutical Research & Development...CompletedDiabetes Mellitus, Type II | Diabetes Mellitus, Non Insulin DependentUnited States, Poland, Bulgaria, India, Malaysia, Romania, Canada, Russian Federation, Argentina, Puerto Rico, Czech Republic, United Kingdom, Mexico
-
Samsung Medical CenterMinistry of Trade, Industry & Energy, Republic of Korea; Korea Evaluation Institute... and other collaboratorsCompletedDiabetes Mellitus | Insulin-dependent Diabetes Mellitus | Insulin HypoglycemiaKorea, Republic of
-
Merck Sharp & Dohme LLCCompletedDiabetes Mellitus, Non-Insulin-Dependent | Type 2 Diabetes Mellitus, Non Insulin Dependent
-
VeraLight, Inc.InLight SolutionsUnknownGestational Diabetes | Insulin Dependent Diabetes | Non Insulin Dependent DiabetesUnited States
-
National Center for Complementary and Integrative...CompletedDiabetes Mellitus, Non-Insulin Dependent | Non-Insulin DependentUnited States
Clinical Trials on Insulin glulisine
-
Profil Institut für Stoffwechselforschung GmbHSanofiCompleted
-
SanofiCompleted
-
SanofiCompletedDiabetes Mellitus, Type 2France, Spain, Italy, Belgium, Germany, Poland, Portugal, Czech Republic, Slovakia, Australia, Netherlands, Sweden, United Kingdom, Switzerland, Romania
-
SanofiTerminated
-
SanofiCompletedDiabetes Mellitus, Type 2Japan
-
SanofiTerminatedDiabetes Mellitus, Type 2Brazil
-
SanofiCompletedDiabetes Mellitus, Type 2United States